Catatonic syndrome during COVID-19 - a case study

Florek, Szymon; Sołtys, Wojciech; Bielówka, Marta; Kołodziejska, Aleksandra

doi:10.12740/pp/onlinefirst/149297

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Case reports have reported success with mirtazapine (Yeh et al, 2010) and clomipramine (Barroso Cañizares et al, 1999) in the maintenance treatment of periodic catatonia in patients with depressive disorder (Yeh et al, 2010). In another case report, authors reported the effectiveness of fluoxetine (20 mg/day) and fluphenazine in the maintenance treatment of periodic catatonia in a patient with schizoaffective disorder (Białek and Jarema, 1999). Case reports or series have reported the role of lamotrigine (Konstantinou et al, 2021) and carbamazepine (Padhy et al, 2011) in the maintenance treatment of periodic catatonia.…”

Section: Periodic Catatoniamentioning

confidence: 99%

Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology

et al. 2023

View full text Add to dashboard Cite

The British Association for Psychopharmacology developed an evidence-based consensus guideline on the management of catatonia. A group of international experts from a wide range of disciplines was assembled. Evidence was gathered from existing systematic reviews and the primary literature. Recommendations were made on the basis of this evidence and were graded in terms of their strength. The guideline initially covers the diagnosis, aetiology, clinical features and descriptive epidemiology of catatonia. Clinical assessments, including history, physical examination and investigations are then considered. Treatment with benzodiazepines, electroconvulsive therapy and other pharmacological and neuromodulatory therapies is covered. Special regard is given to periodic catatonia, malignant catatonia, neuroleptic malignant syndrome and antipsychotic-induced catatonia. There is attention to the needs of particular groups, namely children and adolescents, older adults, women in the perinatal period, people with autism spectrum disorder and those with certain medical conditions. Clinical trials were uncommon, and the recommendations in this guideline are mainly informed by small observational studies, case series and case reports, which highlights the need for randomised controlled trials and prospective cohort studies in this area.

show abstract